| pubmed-article:20156908 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20156908 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:20156908 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:20156908 | lifeskim:mentions | umls-concept:C0019932 | lld:lifeskim |
| pubmed-article:20156908 | lifeskim:mentions | umls-concept:C0246421 | lld:lifeskim |
| pubmed-article:20156908 | lifeskim:mentions | umls-concept:C1506770 | lld:lifeskim |
| pubmed-article:20156908 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:20156908 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20156908 | pubmed:dateCreated | 2010-3-1 | lld:pubmed |
| pubmed-article:20156908 | pubmed:abstractText | To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC). | lld:pubmed |
| pubmed-article:20156908 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20156908 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20156908 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20156908 | pubmed:issn | 1549-490X | lld:pubmed |
| pubmed-article:20156908 | pubmed:author | pubmed-author:JohnstonSteph... | lld:pubmed |
| pubmed-article:20156908 | pubmed:author | pubmed-author:O'RourkeLisaL | lld:pubmed |
| pubmed-article:20156908 | pubmed:author | pubmed-author:SchwartzbergL... | lld:pubmed |
| pubmed-article:20156908 | pubmed:author | pubmed-author:FrancoSandra... | lld:pubmed |
| pubmed-article:20156908 | pubmed:author | pubmed-author:FloranceAllis... | lld:pubmed |
| pubmed-article:20156908 | pubmed:author | pubmed-author:MaltzmanJulie... | lld:pubmed |
| pubmed-article:20156908 | pubmed:author | pubmed-author:SchwarzbergLe... | lld:pubmed |
| pubmed-article:20156908 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20156908 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:20156908 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20156908 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20156908 | pubmed:pagination | 122-9 | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:meshHeading | pubmed-meshheading:20156908... | lld:pubmed |
| pubmed-article:20156908 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20156908 | pubmed:articleTitle | Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. | lld:pubmed |
| pubmed-article:20156908 | pubmed:affiliation | The West Clinic, Memphis, Tennessee, USA. | lld:pubmed |
| pubmed-article:20156908 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20156908 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:20156908 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:20156908 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
